Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corp (NQ: ABUS )

3.750 +0.020 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corp

< Previous 1 2 3 4 5 6 Next >
Why Arbutus Biopharma Is Rocketing Higher Today
A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Why Moderna Shares Are Sliding Today
Moderna Inc (NASDAQ: MRNA) is trading lower Wednesday after The Patent Trial and Appeals Board turned down the company's appeal to invalidate two of Arbutus Biopharma... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent
Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views
Following the market opening Wednesday, the Dow traded up 0.99% to 34,824.47 while the NASDAQ climbed 1.40% to 15,755.57. The S&P also rose, gaining 1.39% to 4,630.57. The U.S... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're starting off the week strong with a dive into the biggest pre-market stock movers for Monday. 
Via InvestorPlace
Understanding Arbutus Biopharma's Unusual Options Activity
Arbutus Biopharma (NASDAQ:ABUS) shares experienced unusua... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
26 Stocks Moving in Monday's Pre-Market Session
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus. Mainz Biomed... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript
ABUS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
21 Stocks Moving in Monday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine... 
Via Benzinga
Exposures COVID-19
41 Stocks Moving In Friday's Mid-Day Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
60 Biggest Movers From Friday
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on Tuesday. SGOCO Group, Ltd. (NASDAQ: SGOC) surged 67... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND... 
Via Benzinga
Arbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript
ABUS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
28 Stocks Moving in Friday's Pre-Market Session
Gainers Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to acquire exclusive rights for assignment of... 
Via Benzinga
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
Via Benzinga
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: 
Via Benzinga
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress... 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
24 Stocks Moving in Friday's Pre-Market Session
Gainers Senseonics Holdings, Inc. (NYSE: SENS) rose 37.1% to $2.81 in pre-market trading after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.